Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
AIM ImmunoTech Inc presented positive data from its ongoing Phase 2a clinical study at the Roswell Park Comprehensive Cancer Center evaluating its flagship.
AIM ImmunoTech Inc presented positive data from its ongoing Phase 2a clinical study at the Roswell Park Comprehensive Cancer Center evaluating its flagship.
/PRNewswire/ Emmaus Life Sciences, Inc. (OTQXC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,.